Dynamic Biotech & Genome Powershares (PBE) 42.99 $PBE
The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX
BE-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
How Will Biotechnology ETFs Finish Out the Year? - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Jun 24, 9:00AM CDT
Which trend will prevail in the volatile biotechnology ETF space.
Two Biotech ETFs Surge on Idenix-Merck Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Jun 10, 1:00PM CDT
Idenix Pharmaceuticals pushes these two biotech ETFs higher ahead of the rivals on Merck buyout.
A Comprehensive Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri May 30, 7:00AM CDT
Despite recent volatility in the space, the longer-term fundamentals remain attractive.
Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.
Powershares Dynamic Biotechnology & Genome Portfolio Has Returned 21.5% Since SmarTrend Recommendation (PBE)
Comtex SmarTrend(R) - Fri Mar 21, 4:58PM CDT
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEXBE) on October 24th, 2013 at $35.71. In approximately 5 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 21.54% as of today's recent price of $43.40.
Powershares Dynamic Biotechnology & Genome Portfolio Shares Up 24.5% Since SmarTrend's Buy Recommendation (PBE)
Comtex SmarTrend(R) - Fri Mar 14, 11:06AM CDT
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEXBE) on October 24th, 2013 at $35.71. In approximately 5 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 24.50% as of today's recent price of $44.46.
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
27.0% Return Seen to Date on SmarTrend Powershares Dynamic Biotechnology & Genome Portfolio Call (PBE)
Comtex SmarTrend(R) - Fri Mar 07, 9:43AM CST
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEXBE) on October 24th, 2013 at $35.71. In approximately 4 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 26.97% as of today's recent price of $45.34.
Top Ranked Healthcare ETF in Focus: XPH - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:01AM CST
This top ranked fund could be a great way to target the strength in the health care market.
The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX
BE-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report). Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
How Will Biotechnology ETFs Finish Out the Year? - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Jun 24, 9:00AM CDT
Which trend will prevail in the volatile biotechnology ETF space.
Two Biotech ETFs Surge on Idenix-Merck Deal - ETF News And Commentary
Sweta Killa - ZACKS - Tue Jun 10, 1:00PM CDT
Idenix Pharmaceuticals pushes these two biotech ETFs higher ahead of the rivals on Merck buyout.
A Comprehensive Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Fri May 30, 7:00AM CDT
Despite recent volatility in the space, the longer-term fundamentals remain attractive.
Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.
Powershares Dynamic Biotechnology & Genome Portfolio Has Returned 21.5% Since SmarTrend Recommendation (PBE)
Comtex SmarTrend(R) - Fri Mar 21, 4:58PM CDT
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEX
BE) on October 24th, 2013 at $35.71. In approximately 5 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 21.54% as of today's recent price of $43.40. Powershares Dynamic Biotechnology & Genome Portfolio Shares Up 24.5% Since SmarTrend's Buy Recommendation (PBE)
Comtex SmarTrend(R) - Fri Mar 14, 11:06AM CDT
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEX
BE) on October 24th, 2013 at $35.71. In approximately 5 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 24.50% as of today's recent price of $44.46. 3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
27.0% Return Seen to Date on SmarTrend Powershares Dynamic Biotechnology & Genome Portfolio Call (PBE)
Comtex SmarTrend(R) - Fri Mar 07, 9:43AM CST
SmarTrend identified an Uptrend for Powershares Dynamic Biotechnology & Genome Portfolio (AMEX
BE) on October 24th, 2013 at $35.71. In approximately 4 months, Powershares Dynamic Biotechnology & Genome Portfolio has returned 26.97% as of today's recent price of $45.34. Top Ranked Healthcare ETF in Focus: XPH - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:01AM CST
This top ranked fund could be a great way to target the strength in the health care market.
